Latest papers

Characterization of cell-cycle-driven and light-driven gene expression in a synchronous culture system in the unicellular rhodophyte Cyanidioschyzon merolae.

Exploring novel targets for antimalarial drug discovery: plasmodial protein kinases.

Leveraging cell cycle analysis in anticancer drug discovery to identify novel plasmodial drug targets.

Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice.

The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.

Targeting the cell cycle and the PI3K pathway: a possible universal strategy to reactivate innate tumor suppressor programmes in cancer cells.

AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.

Non-CDK-bound p27 (p27NCDK) is a marker for cell stress and is regulated through the Akt/PKB and AMPK-kinase pathways

[Mechanisms of transcriptional regulation upon protein phosphorylation by mediator complexes].

Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis.

CKS1B overexpression implicates clinical aggressiveness of hepatocellular carcinomas but not p27(Kip1) protein turnover: an independent prognosticator with potential p27 (Kip1)-independent oncogenic attributes?

CDK inhibitors: from the bench to clinical trials.

Cyclin-dependent kinase inhibitors: a survey of recent patent literature.

Cyclin-dependent kinase inhibitors as anticancer drugs.

Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.

In vitro cell cycle dynamics of primitive hematopoietic cells from human umbilical cord blood.

The anaphase-promoting complex/cyclosome (APC/C): cell-cycle-dependent and -independent functions.

Coming full circle: cyclin-dependent kinases as anti-cancer drug targets.

Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates.

Identification of substrates for cyclin dependent kinases.